Fidelity Growth Company (FDGRX) a Zacks Ranked #1 (Strong Buy) was incepted in January 1983 the fund is managed by the Fidelity Group. The objective of FDGRX is to seek capital appreciation. The management invests primarily in common stocks. FDGRX‘s assets are invested in companies the management believes have above-average growth potential. Growth may be measured by factors such as earnings or revenue. The management may invest FDGRX's assets in domestic and foreign issuers. FDGRX offers dividends and capital gains, if any, in January and December.
This Large Growth fund, as of the last filing, allocates their fund in three major groups; Large Growth, Small Growth and Precious Metal. Further, as of the last filing, Apple Inc, Salesforce.com, Inc and Regeneron Pharmaceuticals, Inc were the top holdings for FDGRX.
The Fidelity Growth Company, managed by Fidelity, carries an expense ratio of 0.82, but it does come with a 0.65% management fee. Moreover, FDGRX requires a minimal initial investment of $2,500.
FDGRX has a history of strong positive total returns for over 10 years. Specifically, the fund’s returns over the 1, 3, 5 year benchmarks; 1 year 16.98%, 3 year 17.33%, and 5 year 17.51%. To see how this fund performed compared in its category, please click here.
FDGRX’s performance, as of the last filing, when compared to funds in its category was in the top 6% in 1 year, top 14% over the past 3 years, and in the 2% over the past 5 years.
About Zacks Mutual Fund Rank
By applying the Zacks Rank to mutual funds, investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward. Pick the best mutual funds with the Zacks Rank.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Get Your Free (FDGRX): Fund Analysis Report
To read this article on Zacks.com click here.